



STATE OF THE ART REVIEW

Cognitive and mental health outcomes in long covid

Eleni Aretouli,¹ Mansoor Malik,² Catherine Widmann,³ Ann M Parker,⁴ Esther S Oh,⁵ Tracy D Vannorsdall⁶

ABSTRACT

Roughly one in five adults who meet criteria for long covid present with objective or subjective cognitive dysfunction or elevated symptoms of depression or anxiety lasting ≥ 12 weeks from an acute covid illness. These neuropsychiatric sequelae have considerable functional consequences at the level of the individual, society, and the broader economy. Neuropsychiatric long covid symptoms are thought to be causally diverse, and a range of risk factors as well as biological, psychological, and environmental mechanisms have been hypothesized to contribute to symptom development and persistence. When present, objective cognitive deficits tend to be modest for most individuals, with some evidence suggesting increased risk of dysfunction and decline specifically for older adults with a history of severe acute illness. Longitudinal data suggest a delayed emergence of psychiatric symptoms may occur in the weeks and months after an acute covid illness. Emerging research points to the early recovery period as a potential window of opportunity for intervention to alter patient trajectories, though evidence based treatment remains lacking.

Introduction

Long covid refers to a range of chronic, systemic, and often disabling health conditions associated with SARS-CoV-2 infection.^{1,2} By September 2024, 5.3% of the US general population reported symptoms lasting three or more months after acute SARS-CoV-2 infection,³ whereas the World Health Organization (WHO) estimates that 10–20% of people infected by SARS-CoV-2 worldwide go on to develop long covid.⁴ Long covid can manifest as profound fatigue, breathlessness and other respiratory conditions, muscle and joint pain, cardiac abnormalities, and a variety of other symptoms resulting from damage to multiple organs and systems.^{5,6} Among the range of symptoms experienced by those with long covid, cognitive and mental health concerns (commonly referred to as neuropsychiatric symptoms), such as “brain fog,” concentration and memory difficulties, depression, and anxiety are especially common,^{7–9} affecting approximately 20.4% of long covid patients.¹⁰ Neuropsychiatric symptoms often persist longer than other long covid symptoms,^{8,11–14} are associated with functional limitations^{7,11,15,16} and ultimately pose considerable burden on individuals, health systems, and the economy.¹⁷

While high quality studies have advanced our understanding of long covid, including neuropsychiatric symptoms, there are methodological challenges inherent to a novel, rapidly expanding

field. Distinct long covid symptom phenotypes have been identified (such as mental/cognitive, cardiac/renal, multidomain).^{18,19} Studies examining long covid as a unitary syndrome may obscure the specific risk factors and mechanisms underlying distinct phenotypes.²⁰ An additional challenge relates to conducting research in the setting of evolving definitions of long covid. Variation in recruitment strategies and the potential for selection bias may skew our understanding of neuropsychiatric sequelae. Careful consideration must also be given to selecting the most appropriate control groups (that is, no covid, prior asymptomatic illness, well recovered). Reliance on subjective ratings rather than objective cognitive testing and differing definitions of cognitive impairment may contribute to discrepant findings across studies. Variable consideration has been given to factors such as acute illness severity, comorbidities, and demographic characteristics.^{21,22} The evolving nature of viral variants along with cultural and temporal shifts in pandemic-related social and behavioral restrictions, vaccination rates, prior infections, and medical practices all demand careful consideration in study design and interpretation. Meta-analyses may produce similar results as they draw on a similar pool of studies while being simultaneously vulnerable to the methodological shortcomings of the parent literature.

This review provides an up-to-date assessment of the functional and economic consequences, nature, severity, and trajectory of neuropsychiatric long covid sequelae. It identifies current knowledge regarding risk factors and proposed mechanistic pathways for symptom development and persistence, and outlines evidence to guide treatment interventions while also highlighting directions for future research.

Epidemiology

The reported prevalence of long covid varies widely by study, time, and data source. Even among high quality studies, data range from conservative estimates of 6.2% of adults who ever had covid-19 to 45% across prospective epidemiologic studies, cross-sectional health surveys, electronic health records (EHR), and systematic reviews and meta-analyses.^{23–26} Reported prevalence estimates may be inflated due to methodological limitations, including self report bias and skewed study populations (that is, surveys may overestimate prevalence due to recall bias). This raises concerns that high-end estimates may not reflect the true population-level risk.

Leveraging pre-covid health status, global estimates suggest 6.2% of symptomatic covid-19 survivors

¹ University of Ioannina, School of the Social Sciences, Department of Psychology, University Campus PC 45110, Ioannina, Greece

² Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, 21287, USA

³ University of Bonn Medical Center, Center for Neurology, 53127 Bonn, North Rhine-Westphalia, Germany; German Center for Neurodegenerative Diseases, 53127 Bonn, North Rhine-Westphalia, Germany

⁴ Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD, 21287, USA; Outcomes After Critical Illness and Surgery (OACIS) Research Group, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA

⁵ Johns Hopkins University School of Medicine, Department of Medicine, Department of Psychiatry and Behavioral Sciences, Department of Pathology, Baltimore, MD, 21287, USA; Johns Hopkins University School of Nursing, Baltimore, MD, 21287, USA

⁶ Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Department of Neurology, Baltimore, MD, 21287, USA

Correspondence to: T D Vannorsdall TVannor1@jhmi.edu
<https://orcid.org/0000-0003-3103-1371>

Cite this as: *BMJ* 2025;390:e081349

<http://doi.org/10.1136/bmj-2024-081349>

Published: 16 July 2025

experience at least one of three common symptom clusters at three months after acute infection: persistent fatigue with pain or mood swings, cognitive problems, or respiratory issues.²⁷ In the US, data from the Medical Expenditure Panel Survey estimated that, by March 2023, 6.9% of all adults had ever had long covid.²⁸ The US Centers for Disease Control and Prevention’s (CDC) Household Pulse Survey reports a fluctuating prevalence of long covid, ranging from a height of 7.6% in summer 2022 to a low of 5.3% at the most recent survey in August–September 2024.³

On a global scale, the cumulative incidence of long covid has steadily increased, with estimates of 65 million cases in 2020, 211 million in 2021, 337 million in 2022, and 409 million in 2023.²⁹ In the US, data from the NIH-funded RECOVER study covering March 2020 to January 2024 reported the excess incidence of long covid—after accounting for background levels of similar symptoms—at 5–6% among adults.³⁰ Incidence rates have demonstrated relative temporal stability with slight transient increases following the emergence of new variants.³⁰

Methods

A literature review was conducted by two of the authors (EA and TDV). We searched PubMed and MedLine databases for studies published from January 2020 to end of June 2024 using the following search terms: (“long covid” or “post-covid” or “covid long-haulers” or “post SARS-CoV-2” or “post-covid-19 condition” or “post-acute sequelae of covid-19” or “chronic covid”) AND (“cognition” or “cognitive dysfunction” or “mental health outcome” or “mental disorder” or “mental health” or “function” or “depression” or “anxiety” or “post-traumatic stress disorder” or “return to work” or “sick leave” or “workforce connection” or “employment”). We also identified articles cited within select publications. We opted

not to include search terms only related to long covid fatigue, as fatigue frequently co-occurs with other neuropsychiatric symptoms of interest as well as physical symptoms of long covid such as pulmonary dysfunction.³¹

We included systematic reviews, meta-analyses, large randomized controlled trials, high quality population-based observational and prospective studies (which we considered as low risk of bias), and clinical guidelines. We also permitted smaller, well designed trials and clinical cohorts to inform our discussion of functional outcomes, mechanistic pathways, and symptom management. We focused on studies assessing outcomes at least three months after the initial SARS-CoV-2 infection where data permitted. As this is not a systematic review, final decisions on study entry were made through a consensus meeting. We excluded studies in animals, children, or specific patient populations and studies that did not explicitly report on cognitive and mental health outcomes associated with covid-19. Case reports and case series were also excluded.

Nomenclature and definition of long covid

A reliable diagnostic marker for long covid is currently lacking, as is a consensus definition or generally agreed set of diagnostic criteria. Hence, a range of terms exist to characterize long covid, including post-covid-19 condition or syndrome (PCC or PCS), post-acute sequelae of SARS-CoV-2 infection (PASC), long-haul covid-19, or chronic covid-19.³² Definitions from national and international organizations differ on clinical criteria, particularly regarding the initial diagnosis of covid-19 (suspected, probable, confirmed with SARS-CoV-2 testing, clinically diagnosed), timing since symptom onset, and duration of symptoms required for long covid diagnosis (see [table1](#)).

Table 1 | Definitions of long covid

Definition	Criteria for diagnosis	Symptom duration requirement	Requirement for confirmed SARS-CoV-2 infection	Strengths	Weaknesses
WHO: Post-Covid-19 Condition (PCC) ^{4 33}	Probable or confirmed SARS-CoV-2 infection with persistent unexplained symptoms	≥2 months	Probable or confirmed	Captures a broad range of cases; accommodates evolving evidence	Loose criteria may include unrelated symptoms; possible overdiagnosis
CDC and US Department of Health and Human Services ³⁴	Persistent symptoms following covid-19	≥4 weeks	Not explicitly required	Early identification of cases; useful for public health tracking	May capture transient postviral symptoms rather than chronic cases
UK NICE: Long covid / Post-Covid-19 Syndrome (PCS) ³⁵	Symptoms persisting or emerging post-covid-19	≥12 weeks	Not explicitly required	Focuses on prolonged symptoms, reducing false positives	May exclude individuals with significant symptoms at earlier time points
National Academies of Arts and Sciences (US) ³⁶	Chronic condition post-SARS-CoV-2 infection, relapsing/remitting or progressive	≥3 months	Recognized or unrecognized infection of any severity	Includes asymptomatic and untested cases; considers chronic disease patterns	Broad inclusion may reduce specificity; difficult to apply in clinical settings

While broader definitions, such as those from the WHO and National Academies, enhance case identification and public health monitoring, they risk overdiagnosis by including individuals with uncertain infection histories or unrelated symptoms. In contrast, the CDC and the UK National Institute for Health and Care Excellence (NICE) definitions apply more stringent criteria, prioritizing specificity for clinical and research use but potentially overlooking early or mild cases. These inconsistencies impact prevalence estimates, clinical diagnosis, and policy development, underscoring the need for harmonized criteria and objective biomarkers to improve diagnostic reliability and research comparability.

Functional and economic outcomes

The impact of cognitive and mental health symptoms associated with long covid is challenging to separate from that attributable to other long covid symptoms or the broader covid-19 pandemic. However, existing evidence highlights the specific contribution of neuropsychiatric distress to functional limitations (that is, ability to work and perform everyday tasks)^{7 16 37 -40} and associated economic burden^{17 41} among affected individuals.

The Canadian COVID-19 Antibody and Health Survey reported that, among >26 000 adults with post-covid-19 condition, 28.0% (95% CI 20.4 to 36.6%) of those with post-covid mood dysfunction (that is,

sadness, pessimism, hopelessness, or depression) indicated that these symptoms often or always limited their daily activities.⁴² This rate was nearly identical to that of survey participants with pre-existing chronic mental health conditions who rated their functioning as often or always limited after their covid-19 illness (28.1% (95% CI 21.2 to 35.8%)). Rates of functional limitations were even greater among those reporting post-covid stress or anxiety (34.2% (95% CI 25.9 to 43.3%)) and post-covid cognitive dysfunction (38.0% (30.1% to 46.5%)) relative to other symptoms. A cross-sectional observational study spanning 31 post-covid clinics in the UK found that fatigue, depression, and perceived cognitive difficulties were significant determinants of occupational and psychosocial functioning among 3754 patients seeking treatment for long covid.⁴³ It is now appreciated that older adults, those hospitalized for covid-19, and those who experienced neurological complications during an acute covid illness tend to experience more pronounced post-covid functional limitations.^{44 45} For example, 1865 out of the 52 759 participants in the Neuro-COVID Italy trial who were hospitalized with covid-19 experienced newly diagnosed neurologic conditions during the acute or post-acute illness phase. While the majority with neurologic symptoms (64.6%) had good functional outcome at 6.7 month follow-up, a considerable proportion with stroke (47.6%), encephalitis (25%), encephalopathy (24.4%), or Guillain-Barré syndrome (23.7%) encountered substantial challenges performing basic activities of daily living.⁴⁴ Additionally, more than half of those with subjective post-covid cognitive dysfunction (56.2%) also reported mild but persistent functional limitations.⁴⁴

Adverse changes in employment status are a common post-covid concern. In an early international online survey of 3762 primarily non-hospitalized patients participating in post-covid support groups, 45.6% (95% CI 43.2 to 48.0%) reported reduced work capacity compared with pre-illness levels. Of working respondents, 86.2% (84.4 to 88.0%) reported that cognitive dysfunction affected their ability to work.⁷ A recent meta-analysis of 19 studies including 21 155 patients from 14 countries concluded that long covid cognitive dysfunction was associated with reduced work capacity and effectiveness as well as increased workplace absenteeism.³⁸ Of the 60.9% who successfully returned to work three months after infection, up to 49.3% required changes in their work assignments or hours.³⁸ A longitudinal, prospective cohort study in the UK revealed that 26.9% of 2469 previously hospitalized patients had changed their occupations within two to three years after their infection, primarily due to health related considerations.¹⁴ Interestingly, both subjective cognitive symptoms and objective

deficits in reaction time and cognitive control were key predictors of occupational change, thus illustrating the pivotal role of cognitive health in maintaining post-covid employment.

Beyond individual health-related concerns, the economic impact of the global SARS-CoV-2 pandemic and long covid in particular, is substantial.¹⁷ The Organization for Economic Co-operation and Development estimated an approximate 0.5% drop in gross domestic product across eight countries in 2024 due to long covid.⁴⁶ In the US alone, the workforce impact of long covid was estimated to be 1.5 billion work hours lost and more than \$152.6 billion in economic impact in 2024.⁴⁶ Previous reports estimated annual lost wages ranging from \$101 to \$430 billion,⁴⁷ potentially reaching nearly \$1 trillion if symptoms persist for at least five years.⁴⁸ The direct cost of treating covid-related mental health issues (that is, depression and anxiety) has been estimated at roughly \$20 000 per person per year, resulting in an estimated cost of \$528 to \$544 billion over five years.^{41 48} Factoring in reduced quality of life, the overall economic toll of long covid is projected at \$2.6 trillion.¹⁷

Mechanisms

The mechanistic pathways of long covid neuropsychiatric symptoms are complex and multifactorial. While many studies have explored pathways related to acute neurological complications, fewer have examined the mechanisms behind persistent cognitive dysfunction and mental health symptoms. Most research has focused on biological mechanisms linked to SARS-CoV-2 infection and its sequelae, with less attention given to indirect and/or psychosocial mechanistic pathways for neuropsychiatric symptoms.

Direct neuroinvasion by SARS-CoV-2, peripheral inflammation and related immune responses, endothelial disruption, and vascular processes such as thrombosis, ischemia, and hypoxia have been reported as potential mechanisms of long covid in humans (see [fig 1](#)).^{49–52} Early research investigated whether SARS-CoV-2 might infect the brain through the olfactory pathway, replicate within neural or glial cells, and cause brain dysfunction.⁵³ However, evidence remains limited.⁵⁰ Some studies indicate that long covid neuropsychiatric dysfunction may result from an overproduction of cytokines, with the related hyperinflammatory response weakening the blood-brain barrier, allowing viral particles, cytokines, and immune cells to enter the central nervous system, potentially altering brain function.^{54 55} Increased permeability of the blood-brain barrier has been observed during acute SARS-CoV-2 infection and thereafter, including among those with persistent cognitive complaints.^{56 57}




Fig 1 | Potential mechanisms of long covid

Proinflammatory and hypercoagulable states associated with covid-19 can increase the risk of serious vascular complications such as ischemic stroke and related cognitive dysfunction.⁵⁸⁻⁶⁰ Microvascular injury in the absence of stroke has been observed in the brains of individuals who died of covid-19.⁶¹ Hypoxia and hypoxemia may further contribute to brain dysfunction via a pathway of metabolic alterations, cell apoptosis, and neural systems dysfunction. Preliminary data have linked post-covid-19 cognitive complaints to cerebral hypoxia among non-hospitalized patients seven months after acute infection.⁶²

Severity of acute illness is associated with various inflammatory markers.⁶³⁻⁶⁷ In the general population, inflammation is associated with greater cognitive and psychiatric dysfunction.⁶⁸⁻⁷¹ Higher aggregate systemic inflammation during acute covid-19 has predicted both depressive symptoms and cognitive performance following hospital discharge.⁷²⁻⁷⁴ Several studies point to specific immune profiles related to long covid neuropsychiatric outcomes. For instance, a cohort study of 2320 individuals found that moderate physical and cognitive symptoms five months after hospitalization were associated with elevated levels of interleukin-6 and CD70 compared with those with mild symptoms.⁷⁵ Inflammatory proteins, including those associated with endothelial repair, neural growth regulation, and cell turnover, have also been significantly elevated in those with severe covid-19 and persistent long covid cognitive and mental health symptoms.⁷⁶

Although these remain promising areas for future investigation, the mechanisms underlying long covid-related neuropsychiatric dysfunction remain speculative. Biomarkers of neuronal injury post-covid, when identified in the blood, cerebrospinal fluid, and

plasma, are not consistently associated with long covid cognitive and mental health outcomes.⁷⁷⁻⁷⁹ Neurofilament light chain (NfL), a marker of axonal injury, has emerged as a potential biomarker for long covid-related neuronal damage, with higher levels correlating with post-covid cognitive deficits.⁸⁰ However, some studies have failed to establish an association between NfL and long term neuropsychiatric symptoms, underscoring the need for further investigation.⁸¹ Structural, functional, and diffusion-weighted magnetic resonance imaging (MRI) as well as nuclear medicine imaging techniques (18F-DG-PET/CT, 18F-Amyloid PET/CT, and SPECT) have also been used to assess individuals with neuropsychiatric long covid symptoms. While individual studies have demonstrated associations with cognitive performance, subjective cognitive complaints, and mental health symptoms, consistent patterns of brain abnormalities have not been established, nor have reproducible links between imaging findings and clinical presentations.⁸²

In addition to pathways associated directly with SARS-CoV-2 infection, a complex range of co-occurring and pre-existing biopsychosocial factors may contribute to the manifestation and persistence of long covid neuropsychiatric symptoms. Individual-level factors, including fatigue, sleep disruption, physical discomfort and pain, autonomic dysfunction (such as postural orthostatic tachycardia syndrome), polypharmacy, substance use, and comorbidities can influence the neuropsychiatric symptom profile in affected individuals.⁸³ In addition, evidence from correlational and experimental paradigms demonstrate that covid-related expectancies are associated with longer symptom duration and the presence of unexplained symptoms, suggesting

that individual beliefs and societal messaging may pose a nocebo effect in vulnerable individuals.⁸⁴⁻⁸⁷

Limited data suggest that, in a proportion of individuals with long covid, symptoms may reflect a somatic symptom disorder.⁸⁸⁻⁸⁹ Long covid and somatic symptom disorder share several predisposing, precipitating, and perpetuating factors including demographic characteristics, psychiatric comorbidities, and adverse childhood experiences.⁸⁸⁻⁹⁰⁻⁹¹ In a cohort of >2800 predominantly middle aged, white, female healthcare workers, childhood abuse showed a dose-dependent relationship with risk of developing post-covid condition, with moderate or severe childhood abuse (reported by 53.2%) linked to a 24% and 42% increased likelihood, respectively.⁹² Early life trauma was hypothesized to have resulted in immune system dysregulation and pro-inflammatory states that heightened susceptibility to both contracting covid-19 and developing long covid. A small single center observational study (n=50) also found that 64% of individuals with persistent neurological symptoms after a mild covid-19 illness met DSM-5 criteria for somatic symptom disorder.⁹³

Clinical data from adults presenting with cognitive concerns after non-severe acute covid-19 illness demonstrate elevated rates of heightened somatic preoccupation often paired with clinically significant symptoms of depression and anxiety.⁹⁴⁻⁹⁵ This symptom pattern has remarkable overlap with that seen in individuals reporting cognitive concerns attributed to post-concussion syndrome.⁹⁵ Further, the stability of the long covid psychological profile over several phases of the pandemic has been interpreted to suggest that, rather than being driven by disease or pandemic-related environmental stressors, a proportion of individuals with long covid may have a pre-covid vulnerability to experiencing emotional distress and maladaptive somatic focus.⁹⁴⁻⁹⁵

Notably, the presence of a somatic symptom disorder does not preclude the existence of demonstrable physical dysfunction. Given the non-specific nature of long covid symptoms and a lack of diagnostic markers, identifying both physical and psychological manifestations of long covid may be important for guiding treatment and optimizing patient outcomes. While somatic symptom disorder is a treatable psychiatric condition,⁹⁶ it remains uncertain whether such approaches will benefit those with long covid. Importantly, data indicate that those presenting for long covid-related clinical neuropsychological services show relatively low rates of invalid symptom presentation (such as amplification) on formal symptom validity testing.⁹⁴ Further, given patient reports of stigmatization and concerns of “gaslighting” by healthcare professionals, enacting approaches to avoid social stigmatization and patient alienation are particularly important in this patient population.⁹⁷⁻⁹⁸

Neuropsychiatric symptoms in long covid

Risk factors

Numerous factors have been examined in relation to long covid neuropsychiatric symptoms. Perhaps the most replicated finding with regard to risk is that a greater proportion of women than men report cognitive dysfunction and psychiatric symptoms following covid-19 and meet criteria for long covid.⁴⁵⁻⁹⁹⁻¹⁰² Age has been found to modify the relation between covid-19 and later outcomes, though findings are conflicting. Multiple studies point to a greater prevalence of long covid-related neuropsychiatric symptoms in younger and middle-aged adults.¹⁰³⁻¹⁰⁵ Conversely, recent systematic reviews and meta-analyses have concluded that older age increases the risk for negative neurocognitive⁹⁻⁴⁵ and mental health outcomes.¹⁰⁶

The association between severity of acute illness and neuropsychiatric symptoms after SARS-CoV-2 infection is complex. Data from patient registries, large epidemiologic studies, and meta-analyses indicate that greater severity of acute illness, typically indexed by the need for hospitalization, is associated with poorer cognitive and mental health outcomes.⁴⁵⁻¹⁰⁷⁻¹¹⁰ However, findings are not uniform, and neuropsychiatric symptoms are also reported at high rates among individuals who experienced less severe acute illness, particularly in treatment-seeking cohorts.⁹⁵⁻¹⁰⁵⁻¹¹¹⁻¹¹³ There are also data indicating that rates of neurocognitive symptoms and new-onset mental health disorders after hospitalization for covid-19 are similar among those hospitalized for non-covid illness of matched severity, suggesting that factors related to severe illnesses and hospitalization rather than unique characteristics of SARS-CoV-2 infection may drive such outcomes.⁸³⁻¹¹⁴

A series of studies demonstrated that vaccination is associated with lower risk for long covid, including cognitive dysfunction⁴⁵⁻¹¹⁵⁻¹¹⁶ and mental health symptoms.¹¹⁷ Data on the risk of neuropsychiatric outcomes by covid-19 variant is mixed. While persistent or increased rates of psychiatric and cognitive diagnoses were reported with the emergence of the later delta and omicron variants,⁵⁸ evidence suggests more recent SARS-CoV-2 variants confer lower risk of long covid¹¹⁸ and are linked to smaller cognitive deficits.⁴⁴⁻¹¹⁵

A range of pre-existing physical health comorbidities (such as cardiovascular disease, obesity, hypertension, sleep apnea) are related to poorer neuropsychiatric outcomes following an acute covid-19 illness.⁴⁵⁻¹¹⁹⁻¹²⁰ Many of these serve as independent of covid-19 risk factors for cognitive dysfunction. Pre-existing mental health conditions and subjective cognitive dysfunction have also emerged as risk factors for more severe acute covid-19 as well as for the development and persistence of long covid neuropsychiatric and somatic symptoms¹²¹⁻¹²² in hospitalized and non-hospitalized patient groups.¹¹³⁻¹²¹⁻¹²⁵ Several studies with pre-existing and early neuropsychiatric data reveal a dose-dependent relationship between early neuropsychiatric symptoms and the risk of developing persistent symptoms following covid-19.¹²²⁻¹²⁶

Cognitive outcomes

Several methods have been used to capture cognitive outcomes associated with long covid, including diagnostic codes documented in electronic health records (EHRs) or assessed via self-reports. While EHR data provide insights into prevalence and symptom trajectories, they present methodological limitations, including missing data, non-participation bias, inconsistent coding practices, and variability in how cognitive outcomes and exposures are recorded.¹²⁷ These factors can lead to underreporting, misclassification, and a lack of granularity regarding cognitive impairments. Cognitive screening instruments, used to assess global cognitive skills, may lack sensitivity to detect subtle declines or distinct domains of dysfunction. Studies utilizing comprehensive, well validated cognitive test batteries are considered the gold standard¹²⁸⁻¹²⁹ as they provide greater specificity, capturing both the nature and severity of cognitive dysfunction post-covid, and serve as more proximal markers of brain function, reducing the risk of misinterpretation inherent in broader EHR-based studies.

EHR data suggest that SARS-CoV-2 infection increases the risk of cognitive disorder diagnosis. For example, a study of >1.5 million US veterans with covid-19 (compared with >5.8 million contemporaneous no-covid-19 controls) found heightened risk for diagnoses of memory dysfunction (hazard ratio 1.77 (95% CI 1.68 to 1.85)) and Alzheimer's disease (HR 2.03 (1.79 to 2.31)) at one year post-illness.¹⁰⁵ A large international study (n=1 487 712) compared

patients with covid-19 with a contemporaneous cohort of matched patients with other respiratory infections: it found an increased risk of cognitive deficit (HR 1.36 (1.33 to 1.39)) and dementia (HR 1.33 (1.26 to 1.41)) remained at two years post-infection in those with a history of covid-19.⁵⁸

Data from subjective symptom reports suggest cognitive dysfunction is one of the more common long covid symptoms.^{9 10} The exact prevalence remains difficult to ascertain given the aforementioned methodological challenges and the overlap between cognitive complaints and other long covid symptoms (for example, depression, myalgic encephalomyelitis/chronic fatigue syndrome).^{130 131} Rates may also be changing over time due to the shifting nature of the covid-19 pandemic.³⁶ At one end of the spectrum, a large, cross-sectional international online survey from 2020 involving primarily non-hospitalized (>91%) covid-19 support group participants reported a 58.4% prevalence (95% CI 56.5% to 60.2%) of cognitive dysfunction six months after infection.⁷ In contrast, a Dutch intensive care unit (ICU) registry of 301 patients found that only 16.2% reported cognitive symptoms at one year after infection,¹³² a rate notably lower than the typical prevalence among ICU survivors before the pandemic (that is, 45% at >6 months).¹³³

A recent systematic review and meta-analysis of 43 studies of those with a history of covid-19 and/or long covid underscores the wide variability in prevalence of subjective cognitive dysfunction, with reports ranging from 15% to 80% at 12 or more weeks after diagnosis and an overall prevalence of 18%.⁹⁹ Finally, in one of the few studies to have statistically adjusted for pre-covid-19 health status and differentiated between covid-19 history and long covid, an estimated

2.2% (95% uncertainty interval (UI) 0.3% to 7.6%) of individuals who experienced a symptomatic SARS-CoV-2 infection and 35.4% (9.4% to 75.1%) of those with long covid reported cognitive difficulties three months after acute illness.²⁷

In an effort to delineate the cognitive profile associated with long covid, there has been an emphasis on objective assessment via validated procedures as well as harmonization of the neuropsychological criteria for the definition of cognitive impairment.¹⁰³ This approach was prompted by concerns regarding response and ascertainment bias (that is, more persons with debilitating long covid symptoms may enroll in online surveys), potential over- or under-estimation of cognitive functioning,¹³⁴ the absent to modest relationship between severity of covid-19 illness and subjective cognitive symptoms, and findings indicating that subjective evaluation is often closely tied to and may be confounded by factors such as mood, anxiety, and fatigue.¹³⁵⁻¹³⁷

Despite substantial research (see [table 2](#) for key studies), a consistent cognitive profile associated with long covid has not emerged. Specific cognitive domains, such as attention/concentration,^{142 147} executive functioning,^{115 138 147 148} processing speed,^{107 146 148} and memory^{115 147} have each been identified as the most prominent areas of cognitive dysfunction associated with long covid. A recent systematic review of 34 studies employing objectively measured cognitive outcomes at least 12 weeks post-illness reported deficits in learning or recall in 8% to 27% of individuals, with executive dysfunction in 5% to 21%, and word finding deficits in 9% to 16%.¹⁴⁹ It is important to acknowledge that several studies reported no cognitive differences between those with persistent symptoms relative to recovered patients or healthy controls.^{142 150}

Table 2 | Summary of select cognitive outcome studies

Study reference	Study design	Sample size and characteristics	Time to assessment (average)	Findings	Conclusions
Becker et al 2023 ¹³⁸	Prospective cohort	G1: 417 covid-19; 8% hospitalized; 15% ED G2: 151 contemporaneous HC	From diagnosis: 11 months	G1>G2: executive functioning (OR 2.2 (CI 1.0 to 4.7)) G1=G2: attention, working memory, processing speed, language, immediate recall, delayed recall, recognition (ORs P>0.05)	Increased odds of executive dysfunction
Cheetham et al 2023 ^{139*}	Prospective cohort	G1: 1737 covid-19; 8.4% hospitalized G2: 495 long covid G3: 1598 contemporaneous HC	From symptom onset: 42 weeks	G2<G3: composite accuracy (adjusted P<0.05), composite within-task reaction time variability (adjusted P<0.05) G2=G3: composite average reaction time (adjusted P>0.05)	Lower cognitive accuracy and greater reaction time within task variability, but not reaction times; effect sizes generally small
Crivelli et al 2022 ¹⁴⁰	Cohort	G1: 45 covid-19; 31% hospitalized G2: 45 contemporaneous HC	From acute illness: 142 days	G1<G2: memory (Cohen's d=0.73, P=0.016), attention (Cohen's d=1.27, P<0.001), executive function (Cohen's d=1.48, P<0.001), language (Cohen's d=0.88, P=0.002) G1=G2: visuospatial skills (P>0.05)	Large deficits in executive functioning and attention; smaller effects for memory and language; no deficits in spatial skills
Delgado-Alonso et al 2022 ¹⁴¹	Cross-sectional	G1: 50 long covid with cognitive complaints; 36% hospitalized; 10% ICU G2: 50 contemporaneous HC	From post-infection: 9.1 months	G1≤G2: attention and processing speed (Cohen's d=0.04 to 0.40, P=0.005 to 0.863), executive function (Cohen's d=0.26 to 0.53, P=0.004 to 0.016), episodic memory (Cohen's d=0.32 to 0.58; P=0.003 to 0.103)	Deficits on select tests of attention, executive function, and episodic memory; effect sizes generally small
Graham et al 2021 ^{142*}	Prospective cohort	100 non-hospitalized with clinical manifestations of covid-19 compatible with IDSA guidelines: G1: 50 BC SARS/covid-19 G2: 50 contemporaneous BC SARS negative	From symptom onset: G1: 4.7 months G2: 5.8 months	G1<normative data: attention (-0.85 SD, P<0.001), working memory (-0.70 SD, P=0.007) G1=G2: all cognitive domains (P≥0.15)	Lower attention and working memory compared to matched US population means but not differing from post-acute non-covid viral syndrome
Hampshire et al 2024 ^{115*}	Observational cohort, community-based	G1: 2580 long covid (ongoing) G2: 1350 prior long covid (symptoms resolved ≥12 weeks) G3: 46261 contemporaneous HC	From infection: >12 weeks	G1<G3: global cognition (-0.42 SD) G1<G3: memory, reasoning, and executive functioning (-0.33 to -0.20 SD) G2<G3: global cognition (-0.2 SD)	Larger cognitive deficits in participants with long covid and resolved long covid compared to HC
Lamontagne et al 2021 ^{143*}	Observational	G1: 50 covid-19; 2% hospitalized comprising three subgroups: G1a: 15 acute covid-19 G1b: 17 PASC (1–4 months post diagnosis) G1c: 15 long covid (>4 months post diagnosis) G2: 50 contemporaneous HC	From infection: 123.6 days	G1b<G2: executive control/conflict reaction time ($\eta^2=0.09$, P=0.01) G1b=G2: alerting, orienting (P>0.05) No group differences: alerting, orienting (P>0.05)	Small executive control deficits exclusively in those 1–4 months post diagnosis, not observed in those ≥4 months post diagnosis
Matias-Guiu et al 2023 ¹⁰³	Case-control	G1: 404 long covid; 26.5% hospitalized; 4.2% ICU G2: 145 HC	From infection: 484.6 days	G1 v G2: attention and processing speed (z=-0.61 to -0.65, ±0.88 to 1.37), executive function (z=-0.41 to -0.53, ±0.81 to 0.89), visuospatial (z=0.08 to -0.06, ±1.23 to 0.86), language (z=-0.07 to 0.0, ±0.81 to 0.62), episodic memory (z=0.04 to -0.33, ±1.22 to 0.96)	Cognitive deficits mainly in attention/processing speed and executive functioning
Ortelli et al 2022 ^{144*}	Case-control	G1: 74 patients with long covid G2: 29 HC	From PCS onset: 126.4 days	G1 <G2: sustained attention (P<0.0001) G1 <G2: executive attention (P=0.036)	Deficits in sustained and executive attention

Table 2 | Summary of select cognitive outcome studies (Continued)

Study reference	Study design	Sample size and characteristics	Time to assessment (average)	Findings	Conclusions
Poletti et al 2022 ¹⁴⁵	Prospective Cohort	G1: 312 covid-19; hospitalized: 86% of whom 4% in ICU G1a: 92 assessed at 1 month G1b: 122 assessed at 3 months G1c: 98 assessed at 6 months G2: 165 pre-pandemic inpatients with MDD G3: 165 pre-pandemic HC	From discharge: 1 to 6 months	G1a=G1b=G1c: global cognitive index (P=0.08) G1>G2: global cognitive index, verbal memory, working memory, psychomotor coordination (P<0.001) G1=G2: verbal fluency, processing speed, executive functioning (P>0.05) G1<G3: global cognitive index, psychomotor coordination, verbal fluency, processing speed, executive functioning (P<0.001) G1=G3: verbal memory, working memory (P>0.05)	Global cognition was stable post-covid; Those infected had poorer global cognition, psychomotor coordination, verbal fluency, processing speed, and executive functioning than HCs but better global cognition, verbal memory, working memory, and psychomotor coordination than MDD
Zhao et al 2024 ^{146*}	Cross-sectional	G1: 270 long covid†; 20.4% hospitalized G2: 63 recovered covid-19; 11.1% hospitalized G3: 113 contemporaneous HC	From diagnosis: G1: 325.7 days G2: 385.6 days	G1<G3: cognitive slowing reaction times (P<0.001), mean accuracy (P<0.001) G1 v G2: cognitive slowing reaction times (P<0.001), mean accuracy (P=0.034)	Moderate to severe cognitive slowing, compared to both HC and those recovered from covid-19

Study inclusion criteria: 1) Use of objective neuropsychological tests or batteries (excluding screening measures), 2) use of data from healthy/no-covid controls rather than published norms (and providing either group performance or deficit prevalence data), 3) cognition assessed a mean of ≥12 weeks from positive covid-19 test/acute illness/hospital discharge, etc., and 4) a total sample size of at least 50.

"Time to assessment" refers to the covid-19 group.

BC SARS = bio-confirmed SARS-CoV-2 infection during acute illness; ED = treated in emergency department; G = group; HC = healthy control; OR = odds ratio; IDSA = Infectious Diseases Society of America; MDD = diagnosis of major depressive disorder; PASC = post-acute sequelae of SARS-CoV-2 infection.

* Denotes use of computerized cognitive test instruments/platform.

† Post-covid-19 syndrome defined by WHO criteria.

‡ Post-covid diagnosed according to NICE criteria.

Overall, the long covid literature indicates that when present, the magnitude of objective neurocognitive dysfunction tends to be mild.^{90 151} In one of the first large (n=12 689) studies of objective cognitive outcomes, Hampshire and colleagues demonstrated that those with a history of covid-19 scored lower on an online cognitive questionnaire after illness compared with pre-pandemic controls.¹⁰⁹ Those who had been ventilated produced a cognitive composite score -0.47 standard deviations (SD) below demographic expectations, with diminishing effect sizes observed for those who did not require mechanical ventilation (-0.26 SD), hospitalization (-0.13 SD), or any medical assistance (-0.07 SD). Participants in the COVID Symptom Study Biobank with symptoms persisting ≥12 weeks demonstrated similarly modest deficits (β =-0.22) relative to covid-negative controls on a smartphone application assessing cognitive accuracy while not differing from those who had recovered from covid-19.¹³⁹

As the majority of covid-19 cases are now of mild to moderate severity, there is particular concern about the cognitive consequences of these milder acute illnesses.^{151 152} A meta-analysis of data published through June 2023 examined cognitive outcomes across 54 studies (>75% of which focused on individuals with long covid or post-acute sequelae of SARS-CoV-2 infection (PASC)) at an average six months from mild to moderate acute covid illness while also exploring mental health outcomes.¹⁵² A small but statistically significant overall effect was observed, with the covid group performing more poorly than healthy controls and/or normative data (g =-0.36 (95% CI -0.45 to -0.28)). The largest effect was observed for cognitive screening measures such as the Montreal

Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE) (g =-0.56 (-0.75 to -0.36)) followed by processing speed (g =-0.44 (-0.57 to -0.32)) and global cognition (g =-0.40 (-0.71 to -0.09)). Larger effect sizes were observed in the presence versus absence of fatigue (g =-0.35 v g =0.02), depression (g =-0.41 v g =-0.24), anxiety (g =-0.35 v g =-0.22) and with greater illness severity. The authors conclude that, absent the presence of psychiatric symptoms, those with mild to moderate acute illness are unlikely to demonstrate clinically meaningful post-covid cognitive deficits. If replicated, these findings suggest that mental health symptoms may serve as a primary target of intervention for long covid neuropsychiatric symptoms.

Cognitive performance validity testing (PVTs) is recommended in long covid clinical care and research as it is a standard of practice for neuropsychological assessment and provides objective evidence regarding the credibility of an examinee's cognitive scores.^{21 153} Clinically, the use of PVTs is essential in demonstrating the veracity of low cognitive scores and guiding appropriate care and determinations (such as benefits eligibility). Applying PVTs in research allows for the exclusion of invalid data that could skew study findings. Studies have generally found PVT failure rates in long covid samples mirror that of non-litigating adults seeking neuropsychological services. For example, of 247 adults evaluated for long covid-related cognitive concerns approximately six months after their acute illness, just 6.4% failed a single PVT and 7.6% failed one or more PVT.¹⁵⁴ The latter group had higher rates of external incentives for poor performance.

Mental health outcomes

The global covid-19 pandemic was associated with an increase in mental health symptoms such as depression and anxiety.^{58 105} While some studies indicate that this phenomenon was transient and symptoms returned to pre-pandemic levels by as early as mid-2020,¹⁵⁵ other studies suggest the prevalence of psychiatric symptoms increased over the early years of the pandemic.¹⁵⁶ Against this backdrop, psychiatric symptoms have emerged as a significant contributor to long covid-related disability.¹⁴⁵

Studies have generally reported increased rates of psychiatric diagnoses following an acute covid-19 illness. A systematic review of 151 studies published through September 2021 estimated depression and post-traumatic stress disorder (PTSD) prevalences to be 18.3% and 17.9%, respectively, when assessed between four and 20 weeks from covid symptom onset.⁹ UK BioBank data from one year after illness similarly demonstrated increased incidence of mental health diagnoses among 26 101 individuals with a history of covid-19 compared with 380 621 contemporary controls (hazard ratio 1.54 (95% CI 1.42 to 1.67)).¹⁵⁷ Electronic health record data from the US Department of Veterans Affairs have shown comparably elevated risk (1.43 (95% CI 1.38 to 1.47)) for a mental health disorder composite one year after covid-19 among 154 068 affected individuals compared with roughly 11 million contemporaneous and historical covid-negative controls. While hospitalization generally increases risk for psychiatric diagnoses both independent of and in the context of covid-19,^{105 158 159} several studies report that rates of psychiatric complications after hospitalization for covid-19 do not differ from those observed following hospitalization for a similarly severe non-covid illness.^{83 160}

Evidence from studies examining rates of elevated psychiatric symptoms, rather than formal diagnoses, is mixed, and few have focused on symptoms persisting ≥ 12 weeks. A systematic review of 23 studies published through October 2021 included individuals with symptoms persisting ≥ 4 weeks and found marked variability in the prevalence of elevated psychiatric symptoms.¹¹³ Rates of anxiety ranged from 6.8% to 47.8%, depression from 4.6% to 35.9%, and PTSD from 13.0% to 42.8%. A review of 33 studies assessing 6743 people one to six months after a covid diagnosis found no compelling evidence of poorer mental health outcomes relative to the general population, with 12.2% reporting PTSD, 11.1% reporting anxiety, and 10.4% reporting depression at >12 weeks after illness.¹⁶¹ The most informative data to date come from a nationally representative US sample of 25 122 adults.¹⁶² A higher prevalence of moderate symptoms of depression (16.8% v 7.1%; adjusted odds ratio (AOR) 1.96 (95% CI 1.51 to 2.55)) and anxiety (16.7% v 6.3%; AOR 2.21 (1.53 to 3.19)) was observed in those with long covid of ≥ 3 months duration compared with non-long covid controls.

Neuropsychiatric symptom trajectories

Given the evolving nature of the pandemic, it is perhaps not surprising that considerable heterogeneity exists with respect to the reported longitudinal course of cognitive and mental health outcomes associated with both symptomatic covid-19 and long covid. Thus far, studies have variably demonstrated remission of neuropsychiatric issues over time, symptom persistence or fluctuation, delayed emergence of such issues, or a deteriorating clinical picture for at-risk populations.

Leveraging pre-pandemic data from a prospective population-based cohort of adults in Ecuador, declines in MoCA cognitive scores at six months were observed among those with a prior covid-19 illness ($n=52$) while scores of unaffected individuals ($n=41$) remained stable ($\beta=-1.37$ (95% CI -2.14 to -0.61), $P<0.001$). MoCA scores rebounded

in the covid group by 12 months' follow-up, suggesting cognitive recovery ($\beta=0.66$ (-0.11 to 1.42), $P=0.092$).¹⁶³ Conversely, a cohort study of adults age ≥ 60 years who had been hospitalized for covid-19 in Wuhan, China, early in the pandemic compared their cognitive functioning against that of unaffected spouses and raised concern for the possibility of progressive cognitive decline over time. At six and 12 months after discharge, a greater proportion of covid survivors with severe acute illness demonstrated mild cognitive impairment (26.5% and 26%, respectively) or dementia (10% and 15%, respectively) compared with those with milder illness and controls ($<5.4\%$ across time points), whose rates of cognitive dysfunction did not differ from each other. Survivors of severe illness were also more likely to show declines across assessments.^{110 164} However, deterioration may be time limited. When followed from 12 to 30 months after discharge, covid survivors showed less steep cognitive decline relative to control groups, and a small proportion (8%) improved over this period.¹⁶⁵ Wang and colleagues have similarly demonstrated increased risk of receiving an Alzheimer's disease diagnosis among older adults in the year following a covid illness compared with those with other respiratory illnesses.¹⁶⁶ However, findings are not consistent across research teams,¹⁶⁷ and a recent meta-analysis found that, although dementia risk is elevated among older adults after covid-19, this risk does not exceed that observed for other respiratory infections.¹⁶⁸

Most definitions of long covid permit both persistence of early symptoms as well as a delayed emergence of symptoms after the initial covid-19 illness. A meta-analysis including both hospitalized and non-hospitalized patients reported increased prevalence of anxiety and depression among studies assessing symptoms ≥ 6 months after covid relative to 3-6 months after acute illness, whereas rates of subjective cognitive dysfunction remained stable across assessment periods.¹³ Although these are cross-sectional data, they could suggest that psychiatric symptoms are more likely to emerge rather than persist post-infection. Longitudinal studies tend to support this contention. In a prospective, longitudinal cohort study of hospitalized patients comparing psychiatric symptoms and cognitive performance at 6-12 months versus 2-3 years after illness, depression and anxiety both worsened over time in those with early symptoms while they also emerged as new symptoms in previously unaffected individuals. Degree of recovery by six months predicted persistence of later depression, anxiety, and subjective cognitive dysfunction, whereas only early cognitive scores predicted later cognitive test performance.¹⁴ Further, a prospective cohort study of digitally acquired cognitive test data from the UK Biobank demonstrated persistent cognitive deficits at nearly two years after infection, particularly in those with more severe acute illness and exclusively among those reporting unresolved covid symptoms.¹³⁹ Improvements in psychological distress partially mediated the observed cognitive recovery, suggesting a potential target for early intervention.

Symptom management

Given the phenotypic variability of long covid neuropsychiatric presentations, a patient-centered or individualized treatment approach is recommended.^{35 137} Clinical care ideally occurs in a multidisciplinary clinical settings with access to medical providers, mental health specialists (such as neuropsychologists, rehabilitation or health psychologists), speech language pathologists, and physical and occupational therapists with expertise in long covid (see [fig 2](#)).¹⁶⁹⁻¹⁷¹ Logistical challenges are associated with establishing such programs, and many individuals with long covid are not able to access these services even in high-income countries.^{172 173} In

response, ongoing trials are exploring methods to expand and refine long covid care via a range of care delivery models.¹⁷⁴




Fig 2 | Optimal clinical care of patients with long covid

Before initiating management of neuropsychiatric symptoms, a thorough assessment should gather information on acute covid-19 symptoms, vaccination status, symptom course, pre-existing conditions and symptoms, and potential contributing factors.¹⁷⁵ Workups to reveal or rule out other causes of cognitive dysfunction or mental health symptoms may be useful (such as thyroid functioning, vitamin B12 levels, polysubstance use). It is recommended that neuropsychiatric symptoms and functioning be assessed using validated measures that allow for tracking of progress over time.^{170 176 177} Although a Delphi consensus study failed to identify optimal tools for long covid neuropsychiatric assessment,¹⁷⁷ the GAD-7,¹⁷⁸ PTSD Checklist for DSM-5,¹⁷⁹ Cognitive Failures Questionnaire,¹⁸⁰ and the Montreal Cognitive Assessment-Telephone version¹⁸¹ were most highly rated. The NeuroCOVID International Neuropsychology Taskforce has recommended a harmonized, flexible set of tools for assessing both subjective and objective cognition in adults with long covid, including incorporation of cognitive performance validity testing.¹⁷⁶ The American Academy of Physical Medicine and Rehabilitation (AAPMR) and long covid neuropsychology experts have issued similar guidance concerning instruments for use in this population.^{170 175}

Limited evidence exists to guide management of long covid neuropsychiatric symptoms. The quality of existing studies is generally weak, with most evidence stemming from case reports and small open label trials. A 2023 scoping review found only four of 17 mental health intervention studies were controlled trials,¹⁸² and a 2024 review reported just 7% of psychological trials specifically targeted long covid-related mental health concerns.¹⁸³ Encouragingly, the 2022 National Health Interview Survey found most US adults with long covid-related depression (71.8%) or anxiety (65.1%) had received mental health treatment in the prior year, though they were more likely to report cost related barriers

compared with other US adults without long covid (adjusted odds ratio 2.12 (95% CI 1.65 to 2.73)).¹⁶²

Interventions for cognitive dysfunction recommended by the WHO and/or AAPMR include cognitive rehabilitation, self management strategies, use of compensatory and assistive technology, and environmental modifications.^{137 170} Suggestions for addressing mental health symptoms include cognitive behavioral therapy (CBT), with additional components of acceptance and commitment therapy (such as validating the patient experience), mindfulness approaches, physical activity, and peer support as well as consideration of pharmacological intervention. Providing psychoeducation regarding biological, psychological, and social contributions to symptoms and their persistence is also emphasized.

Of the relatively few non-pharmacological trials in long covid, most have applied CBT principles and/or multidisciplinary programs and have targeted symptoms of anxiety, depression, and cognitive concerns.¹⁸⁴ A randomized clinical trial compared CBT versus usual care to tackle severe fatigue in 114 adults with long covid.¹⁸⁵ The intervention significantly improved both fatigue (Cohen's $d=0.69$) and subjective cognitive functioning (Cohen's $d=0.68$) at six months' follow-up. In one of the largest intervention trials to date, an eight week structured online group physical and mental health program was compared with care as usual among 585 formerly hospitalized individuals with physical and/or mental health symptoms of long covid.¹⁸⁶ The intervention was associated with improved symptoms of depression (adjusted mean difference 1.39 (95% CI 0.06 to 2.71)) but not subjective cognitive dysfunction, with benefits that persisted at 12 months. Other promising non-pharmacological approaches include neuromodulation via direct current stimulation (tDCS), transcranial pulse stimulation, or transcranial magnetic stimulation.¹⁸⁷ The ongoing NIH-funded RECOVER-NEURO randomized clinical trial is comparing the efficacy of computerized

cognitive rehabilitation with and without goal management training and tDCS to improve cognitive functioning in adults with long covid.¹⁸⁸

There is little controlled evidence to guide the choice of medications. However, an eight week randomized controlled trial found that selective serotonin reuptake inhibitors (SSRIs) effectively reduced depressive symptoms in those with long covid-related depression, including among those with pre-covid psychiatric symptoms.¹⁸⁹ SSRIs are hypothesized to affect long covid depressive symptomatology via effects on covid-related inflammation (see Mazza et al¹⁸⁹ for an in-depth discussion). Low dose naltrexone (LDN) has been widely used to target long covid fatigue, with studies suggesting more widespread benefit. An opiate antagonist, LDN is hypothesized to target both immunomodulatory and anti-inflammatory pathways that are thought to play an etiological role in long covid symptom development and persistence.¹⁰¹ In a single-center study, 52 patients treated with LDN showed improvement in subjective ratings of concentration among other outcomes.¹⁹⁰ Similarly, in a retrospective study, 62.7% of patients treated with LDN (n=59) reported improvement in at least one long covid neurocognitive symptom.¹⁹¹ Finally, a 16 week, randomized, placebo controlled, phase II trial of LDN is underway in Canada and includes mood and anxiety symptoms as secondary outcomes.¹⁹²

Emerging treatments

A 2022 review of clinicaltrials.gov, a trial registry by the US National Library of Medicine, and the International Clinical Trials Registry, showed 41 long covid mental health interventional trials, ranging from nutritional supplements to CBT and neurorehabilitation.¹⁹³ Several promising ongoing pharmacological interventions are evaluating C1 esterase inhibitor, atorvastatin, donepezil, vortioxetine, nirmatrelvir/ritonavir (Paxlovid), and marrow stromal cell infusion.¹⁹⁴ Given the extremely rapid pace of covid-19 research, it is expected that more pragmatic treatment guidelines will continue to emerge. Further, the heterogeneous nature of long covid suggests that it may be well suited to a precision medicine approach wherein treatment is tailored to individual patient phenotypes based on their risk factors, illness and treatment characteristics, symptom manifestation, etc.¹⁹⁵

Guidelines

As an evidence based pathway for managing long covid neuropsychiatric symptoms has yet to emerge, NICE, WHO, and AAPMR have published guidelines for providing long covid care in community settings.^{35 137 169 170} Most recently in February 2025, the CDC issued an updated Clinical Overview of Long COVID.¹⁹⁶ Common themes across guidelines include the importance of applying a person-centered approach and establishing a supportive and collaborative therapeutic milieu while also referring patients to specialists. The NICE, WHO, and AAPMR guidelines note the importance of using validated instruments to capture cognitive functioning and mental health symptoms, and both WHO and AAPMR specifically note the importance of assessing for other factors that may contribute to a patient's symptom presentation (such as fatigue, mental health symptoms, comorbidities, polypharmacy).^{137 170} WHO, AAPMR, and CDC recommend implementing psychological and behavioral treatment strategies with an existing evidence base built on the treatment of other post-viral illnesses and medical conditions with high rates of mental health and cognitive sequelae (such as post-treatment Lyme disease syndrome, fibromyalgia).^{137 169 170} Such interventions share the goals of improving psychiatric distress, functioning, and quality of life while emphasizing functionality rather than causality in the

treatment process.¹⁹⁷ WHO and AAPMR provide more detailed guidance specific to the management of neuropsychiatric symptoms relative to other guidelines.

Conclusions

About five years after the onset of the covid-19 pandemic, a reliable diagnostic marker for long covid is lacking, as is a consensus definition or generally agreed upon set of diagnostic criteria. The nature and trajectories of post-covid neuropsychiatric symptoms, their risk factors and mechanistic pathways, and their socioeconomic impact are only beginning to come into view. Long term cognitive and mental health sequelae of covid-19 remain prevalent, with nearly one in five affected adults demonstrating or reporting persistent cognitive, mood, or anxiety symptoms at ≥ 12 weeks after an acute covid illness. While objective cognitive deficits are largely modest in magnitude, both cognitive and psychiatric symptoms serve as substantial contributors to reduced functioning and employment among those with long covid. Some patient populations, such as older adults with more severe acute illness, may be at particular risk for persistent long covid-related cognitive dysfunction, while those with pre-existing neuropsychiatric symptoms may be at heightened risk for long covid-related mental health symptoms. Evidence based treatments are lacking, and existing guidelines recommend interventions with empirical support for use in other patient populations. Additional work aimed at understanding the full complement of antecedent, illness, and psychosocial mechanisms of long covid-related neuropsychiatric symptoms will be critical for the development of effective treatment strategies.

Knowledge synthesis

- There is no reliable diagnostic marker for neuropsychiatric symptoms of long covid
- Methodological heterogeneity and the evolving nature of the pandemic have contributed to discrepant findings concerning long covid-related neuropsychiatric symptoms
- These symptoms are associated with functional, occupational, and economic burden and may be more pronounced in elderly people and those who had severe acute covid-19
- Potentially interactive pathways include immune and inflammatory responses, endothelial disruption, and vascular processes. Symptoms may also arise due to, or be complicated by, co-occurring symptoms, conditions, and interventions. For a subset, they may reflect a manifestation or exacerbation of pre-existing symptoms or vulnerabilities and may be influenced by early life adversities and expectancies
- Risk factors include female sex, vaccination status, emergence of new variants, and physical and psychiatric comorbidities. Increased age and severity of acute illness are generally associated with greater objective cognitive dysfunction, while less severe acute illness and younger age are common features among those presenting for neuropsychiatric treatment
- Cognitive testing provides a more direct measure of brain function relative to symptom reports, and recommended instruments and batteries have been developed
- A consistent cognitive profile has not emerged. When deficits are present, effect sizes tend to be small to moderate across domains of attention, processing speed, executive functioning, and memory and more pronounced in the context of severe acute illness, fatigue, and psychiatric symptoms
- There is evidence for symptom remission, persistence, fluctuation, and delayed emergence, which is consistent with current case definitions of long covid. Preliminary data suggest the early recovery

period may reflect a window of opportunity for mitigating negative long term neuropsychiatric outcomes

- Clinical care should take a person-centered approach, gather a comprehensive history, consider contributing factors, use validated screening and assessment instruments, and refer to specialists
- Providers should aim to form a trusting therapeutic alliance that validates the patient experience while providing psychoeducation, implementing interventions with empirical evidence from other health conditions, and focusing on functioning rather than causality
- Interventions may include cognitive rehabilitation and compensatory strategies, psychotherapy (such as CBT, ACT), mindfulness, physical activity, peer support, and pharmacotherapy (such as SSRIs, LND). These, as well as non-invasive brain stimulation and a range of pharmacological agents, are under active investigation as potential tools to address neuropsychiatric symptoms of long covid

Questions for further research

- What are the optimal diagnostic criteria for identifying long covid?
- How are pre-existing neuropsychiatric symptoms, conditions, and risk factors best conceptualized within the framework of long covid?
- Can identifying phenotypic profiles characterizing the cognitive and mental health features of long covid, in combination with other risk factors or biomarkers, aid in the effective personalization of long covid care?
- What are the most efficacious pharmacological, psychological, behavioral, and brain stimulation treatments for addressing cognitive and mental health symptoms in long covid?
- What is the optimal time in the recovery process to intervene in order to prevent or ameliorate neuropsychiatric long covid symptoms?
- How can providers and researchers reduce stigma associated with experiencing and seeking care for cognitive and mental health symptoms of long covid?

How patients were involved in the creation of this article

We have drawn on the clinical experience of addressing the cognitive and mental health concerns of patients within a covid-19 multidisciplinary care model that incorporates neuropsychology, rehabilitation psychology, and psychiatry services. The perspectives of long covid patients and caregivers were shared with author MM, whose moderated discussion of patients' lived experience with long covid is freely available online.¹⁹⁸

A patient with long covid and associated cognitive and mental health concerns provided a critique of our review before submission. Their input highlighted issues related to the challenges of living with symptoms for which there may not be a clearly identifiable cause or definitive diagnostic test. Their input led us to highlight concerns regarding stigma from society and the potential for patients to feel dismissed by care providers. Our patient shared the importance of supportive provider communication. This specifically included the value of providers acknowledging that much remains to be learnt about treating long covid-related neuropsychiatric symptoms and the value of sharing the scientific basis for implementing interventions that are lacking evidence in long covid but have been shown to improve symptoms or functioning in other health conditions.

Competing interests: None declared

We thank the patients who have shared their experiences and informed our understanding of living with long covid.

- 1 National Academies of Sciences, Engineering, and Medicine. *Long-term health effects of COVID-19: Disability and function following SARS-CoV-2 infection*. National Academies Press, 2024. <https://www.nap.edu/catalog/27756>.
- 2 Ely EW, Brown LM, Fineberg HV. National Academies of Sciences, Engineering, and Medicine Committee on Examining the Working Definition for Long Covid. Long covid defined. *N Engl J Med* 2024;391:53. doi: 10.1056/NEJMs2408466 PMID: 39083764

- 3 National Center for Health Statistics. Long COVID. 2024. <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>
- 4 World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. 6 October 2021. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
- 5 Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *BMJ* 2021;374:. doi: 10.1136/bmj.n1648 PMID: 34312178
- 6 Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023;21:46. doi: 10.1038/s41579-022-00846-2 PMID: 36639608
- 7 Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019 PMID: 34308300
- 8 Giussani G, Westenberg E, Garcia-Azorin D, et al. Global COVID-19 Neuro Research Coalition. Prevalence and Trajectories of post-COVID-19 neurological manifestations: a systematic review and meta-analysis. *Neuroepidemiology* 2024;58:33. doi: 10.1159/000536352 PMID: 38272015
- 9 Zeng N, Zhao YM, Yan W, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. *Mol Psychiatry* 2023;28:33. doi: 10.1038/s41380-022-01614-7 PMID: 35668159
- 10 van der Feltz-Cornelis C, Turk F, Sweetman J, et al. Prevalence of mental health conditions and brain fog in people with long COVID: A systematic review and meta-analysis. *Gen Hosp Psychiatry* 2024;88:22. doi: 10.1016/j.genhosppsych.2024.02.009.
- 11 Franco JVA, Garegnani LI, Metzendorf MI, Heldt K, Mumm R, Scheidt-Nave C. Post-covid-19 conditions in adults: systematic review and meta-analysis of health outcomes in controlled studies. *BMJ Med* 2024;3:e000723. doi: 10.1136/bmjmed-2023-000723 PMID: 38293681
- 12 Kim Y, Bae S, Chang HH, Kim SW. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. *Sci Rep* 2023;13:. doi: 10.1038/s41598-023-36995-4 PMID: 37433819
- 13 Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. *J Neurol Sci* 2022;434:120162. doi: 10.1016/j.jns.2022.120162 PMID: 35121209
- 14 Taquet M, Skorniewska Z, De Deyn T, et al. PHOSP-COVID Study Collaborative Group. Cognitive and psychiatric symptom trajectories 2-3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK. *Lancet Psychiatry* 2024;11:708. doi: 10.1016/S2215-0366(24)00214-1 PMID: 39096931
- 15 Bek LM, Berentschot JC, Hellemons ME, et al. CO-FLOW collaboration group. Return to work and health-related quality of life up to 1 year in patients hospitalized for COVID-19: the CO-FLOW study. *BMC Med* 2023;21:. doi: 10.1186/s12916-023-03083-3 PMID: 37784149
- 16 Jaywant A, Gunning FM, Oberlin LE, et al. Cognitive symptoms of post-COVID-19 condition and daily functioning. *JAMA Netw Open* 2024;7:e2356098. doi: 10.1001/jamanetworkopen.2023.56098 PMID: 38353947
- 17 Cutler DM, Summers LH. The COVID-19 pandemic and the \$16 trillion virus. *JAMA* 2020;324:6. doi: 10.1001/jama.2020.19759 PMID: 33044484
- 18 Ozonoff A, Jayavelu ND, Liu S, et al. IMPACC Network. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. *Nat Commun* 2024;15:. doi: 10.1038/s41467-023-44090-5 PMID: 38172101
- 19 Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. *Nat Med* 2023;29:35. doi: 10.1038/s41591-022-02116-3 PMID: 36456834
- 20 Prabhakaran D, Day GS, Munipalli B, et al. Neuropsychotypes of COVID-19: Risk factors and recovery outcomes. *Brain Behav Immun Health* 2023;30:100648. doi: 10.1016/j.bbih.2023.100648 PMID: 37293441
- 21 Becker JH, Vannorsdall TD, Weisenbach SL. Evaluation of post-COVID-19 cognitive dysfunction: recommendations for researchers. *JAMA Psychiatry* 2023;80:6. doi: 10.1001/jamapsychiatry.2023.2820 PMID: 37585198
- 22 Høeg TB, Ladhani S, Prasad V. How methodological pitfalls have created widespread misunderstanding about long COVID. *BMJ Evid Based Med* 2024;29:6. doi: 10.1136/bmjebm-2023-112338 PMID: 37748921
- 23 Adjaye-Gbewonyo D, Vahratian A, Perrine CG, Bertolli J. Long COVID in Adults: United States, 2022. NCHS Data Brief No 480. 2023. <https://www.cdc.gov/nchs/products/databriefs/db480.htm>.
- 24 O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. *EClinicalMedicine* 2022;55:101762. doi: 10.1016/j.eclinm.2022.101762 PMID: 36474804
- 25 Oelsner EC, Sun Y, Balte PP, et al. Epidemiologic features of recovery from SARS-CoV-2 infection. *JAMA Netw Open* 2024;7:e2417440. doi: 10.1001/jamanetworkopen.2024.17440 PMID: 38884994
- 26 Chen C, Haupt SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. *J Infect Dis* 2022;226:607. doi: 10.1093/infdis/jiac136 PMID: 35429399
- 27 Wulf Hanson S, Abbafati C, Aerts JG, et al. Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022;328:15. doi: 10.1001/jama.2022.18931 PMID: 36215063
- 28 Fang Z, Ahnrsbrak R, Rekito A. Evidence mounts that about 7% of US adults have had long COVID. *JAMA* 2024;332:6. doi: 10.1001/jama.2024.11370 PMID: 38848092
- 29 Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. *Nat Med* 2024;30:64. doi: 10.1038/s41591-024-03173-6 PMID: 39122965

- 30 Mandel H, Yoo YJ, Allen AJ, et al. Long-COVID incidence proportion in adults and children between 2020 and 2024. *Clin Infect Dis* 2025;ciaf046. doi: 10.1093/cid/ciaf046 PMID: 39907495
- 31 Sandler CX, Wyller VBB, Moss-Morris R, et al. Long COVID and post-infective fatigue syndrome: a review. *Open Forum Infect Dis* 2021;8:ofab440. doi: 10.1093/ofid/ofab440 PMID: 34631916
- 32 Munblit D, O'Hara ME, Akrami A, Perego E, Oliaro P, Needham DM. Long COVID: aiming for a consensus. *Lancet Respir Med* 2022;10:4. doi: 10.1016/S2213-2600(22)00135-7 PMID: 35525253
- 33 Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JW. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* 2022;22:7. doi: 10.1016/S1473-3099(21)00703-9 PMID: 34951953
- 34 Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. 2024. <https://www.cdc.gov/covid/long-term-effects/index.html>.
- 35 National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NICE guideline NG188). 2020. <https://www.nice.org.uk/guidance/ng188>.
- 36 National Academies of Sciences Engineering and Medicine. A Long COVID definition: a chronic systemic disease state with profound consequences. 2024. <https://nap.nationalacademies.org/catalog/27768/a-long-covid-definition-a-chronic-systemic-disease-state-with>.
- 37 Nielsen TB, Leth S, Pedersen M, et al. Mental fatigue, activities of daily living, sick leave and functional status among patients with long COVID: a cross-sectional study. *Int J Environ Res Public Health* 2022;19:.. doi: 10.3390/ijerph192214739 PMID: 36429458
- 38 Ottiger M, Poppel I, Sperling N, Schlesinger T, Müller K. Work ability and return-to-work of patients with post-COVID-19: a systematic review and meta-analysis. *BMC Public Health* 2024;24:.. doi: 10.1186/s12889-024-19328-6 PMID: 38973011
- 39 Pizarro-Pennaroli C, Sánchez-Rojas C, Torres-Castro R, et al. Assessment of activities of daily living in patients post COVID-19: a systematic review. *PeerJ* 2021;9:e11026. doi: 10.7717/peerj.11026 PMID: 33868804
- 40 Suran M. Long COVID linked with unemployment in new analysis. *JAMA* 2023;329:2. doi: 10.1001/jama.2023.0157 PMID: 36790796
- 41 Bach K. Is 'long Covid' worsening the labor shortage? Brookings, 2022. <https://www.brookings.edu/articles/is-long-covid-worsening-the-labor-shortage/>.
- 42 Government of Canada. COVID-19: Longer-term symptoms among Canadian adults. Fourth report. 2024. <https://health-infobase.canada.ca/covid-19/post-covid-condition/>
- 43 Walker S, Goodfellow H, Pookarnjanamorakot P, et al. Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. *BMJ Open* 2023;13:e069217. doi: 10.1136/bmjopen-2022-069217 PMID: 37286327
- 44 Baretta S, Cristillo V, Camera G, et al. Neuro-COVID Italy. Incidence and long-term functional outcome of neurologic disorders in hospitalized patients with COVID-19 infected with pre-omicron variants. *Neurology* 2023;101:903. doi: 10.1212/WNL.0000000000207534 PMID: 37414564
- 45 Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. *JAMA Intern Med* 2023;183:80. doi: 10.1001/jamainternmed.2023.0750 PMID: 36951832
- 46 Baxa M. An incomplete picture: understanding the burden of long COVID. *Economist Impact* 2024. <https://impact.economist.com/health/incomplete-picture-understanding-burden-long-covid>.
- 47 Mirin AA. A preliminary estimate of the economic impact of long COVID in the United States. *Fatigue* 2022;10:9. doi: 10.1080/21641846.2022.2124064.
- 48 Cutler DM. The costs of long COVID. *JAMA Health Forum* 2022;3:e221809.
- 49 Brown RL, Benjamin L, Lunn MP, et al. Pathophysiology, diagnosis, and management of neuroinflammation in covid-19. *BMJ* 2023;382:e073923. doi: 10.1136/bmj-2022-073923 PMID: 37595965
- 50 Meinhardt J, Streit S, Dittmayer C, Manitus RV, Radbruch H, Heppner FL. The neurobiology of SARS-CoV-2 infection. *Nat Rev Neurosci* 2024;25:42. doi: 10.1038/s41583-023-00769-8 PMID: 38049610
- 51 Perumal R, Shunmugam L, Naidoo K, et al. Long COVID: a review and proposed visualization of the complexity of long COVID. *Front Immunol* 2023;14:1117464. doi: 10.3389/fimmu.2023.1117464 PMID: 37153597
- 52 Saxena A, Mautner J. A disease hidden in plain sight: pathways and mechanisms of neurological complications of post-acute sequelae of COVID-19 (NC-PASC). *Mol Neurobiol* 2024; 62:47. PMID: 39133434
- 53 Stein SR, Ramelli SC, Grazioli A, et al. NIH COVID-19 Autopsy Consortium. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. *Nature* 2022;612:63. doi: 10.1038/s41586-022-05542-y PMID: 36517603
- 54 Krasemann S, Haferkamp U, Pfefferle S, et al. The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. *Stem Cell Reports* 2022;17:20. doi: 10.1016/j.stemcr.2021.12.011 PMID: 35063125
- 55 Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. *Signal Transduct Target Ther* 2021;6:.. doi: 10.1038/s41392-021-00719-9 PMID: 34489403
- 56 Bonetto V, Pasetto L, Lisi I, et al. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. *Front Immunol* 2022;13:1070379. doi: 10.3389/fimmu.2022.1070379 PMID: 36591311
- 57 Greene C, Connolly R, Brennan D, et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. *Nat Neurosci* 2024;27:32. doi: 10.1038/s41593-024-01576-9 PMID: 38388736
- 58 Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. *Lancet Psychiatry* 2022;9:27. doi: 10.1016/S2215-0366(22)00260-7 PMID: 35987197
- 59 Tu TM, Seet CYH, Koh JS, et al. Acute ischemic stroke during the convalescent phase of asymptomatic COVID-19 infection in men. *JAMA Netw Open* 2021;4:e217498. doi: 10.1001/jamanetworkopen.2021.7498 PMID: 33885771
- 60 Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med* 2020;382:e38. doi: 10.1056/NEJMc2007575 PMID: 32268022
- 61 Lee MH, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with Covid-19. *N Engl J Med* 2021;384:3. doi: 10.1056/NEJMc2033369 PMID: 33378608
- 62 Adingupu DD, Soroush A, Hansen A, Twomey R, Dunn JF. Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19. *J Neurol* 2023;270:14. doi: 10.1007/s00415-023-11767-2 PMID: 37216689
- 63 Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med* 2021;2:100287. doi: 10.1016/j.xcrm.2021.100287 PMID: 33969320
- 64 Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. *Autoimmun Rev* 2020;19:102567. doi: 10.1016/j.autrev.2020.102567 PMID: 32373632
- 65 Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol* 2020;92:8. doi: 10.1002/jmv.25801 PMID: 32253759
- 66 Shi L, Lu ZA, Qie JY, et al. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic. *JAMA Netw Open* 2020;3:e2014053. doi: 10.1001/jamanetworkopen.2020.14053 PMID: 32609353
- 67 Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. SARIC4C investigators. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. *Sci Immunol* 2021;6:eabg9873. doi: 10.1126/sciimmunol.abg9873 PMID: 33692097
- 68 Fourrier C, Singhal G, Baune BT. Neuroinflammation and cognition across psychiatric conditions. *CNS Spectr* 2019;24:15. doi: 10.1017/S1092852918001499 PMID: 30714555
- 69 Lamers F, Milaneschi Y, Smit JH, Schoevers RA, Wittenberg G, Penninx BWJH. Longitudinal association between depression and inflammatory markers: results from the Netherlands study of depression and anxiety. *Biol Psychiatry* 2019;85:37. doi: 10.1016/j.biopsych.2018.12.020 PMID: 30819515
- 70 Salim S, Chugh G, Asghar M. Inflammation in anxiety. *Adv Protein Chem Struct Biol* 2012;88:25. doi: 10.1016/B978-0-12-398314-5.00001-5 PMID: 22814704
- 71 Tegeler C, O'Sullivan JL, Bucholtz N, et al. The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive function—data from the Berlin Aging Study II. *Neurobiol Aging* 2016;38:7. doi: 10.1016/j.neurobiolaging.2015.10.039 PMID: 26827649
- 72 Evans RA, McAuley H, Harrison EM, et al. PHOSP-COVID Collaborative Group. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *Lancet Respir Med* 2021;9:87. doi: 10.1016/S2213-2600(21)00383-0 PMID: 34627560
- 73 Mazza MG, Palladini M, De Lorenzo R, et al. COVID-19 BioB Outpatient Clinic Study group. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain Behav Immun* 2021;94:47. doi: 10.1016/j.bbi.2021.02.021 PMID: 33639239
- 74 Taquet M, Skorniewska Z, Hampshire A, et al. PHOSP-COVID Study Collaborative Group. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. *Nat Med* 2023;29:508. doi: 10.1038/s41591-023-02525-y PMID: 37653345
- 75 Evans R. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. *Lancet Respir Med* 2022;10:doi: 10.1016/S2213-2600(22)00127-8.
- 76 Liew F, Efsthathiou C, Fontanella S, et al. PHOSP-COVID collaborative group | SARIC investigators. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. *Nat Immunol* 2024;25:21. doi: 10.1038/s41590-024-01778-0 PMID: 38589621
- 77 Comeau D, Martin M, Robichaud GA, Chamard-Witkowski L. Neurological manifestations of post-acute sequelae of COVID-19: which liquid biomarker should we use? *Front Neurol* 2023;14:1233192. doi: 10.3389/fneur.2023.1233192 PMID: 37545721
- 78 Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. *Ann Intern Med* 2022;175:79. doi: 10.7326/M21-4905 PMID: 35605238
- 79 Taquet M, Skorniewska Z, Zetterberg H, et al. PHOSP-COVID Study Collaborative Group. Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. *Brain Commun* 2023;6:fcad357. doi: 10.1093/braincomms/fcad357 PMID: 38229877
- 80 Gutman EG, Salvio AL, Fernandes RA, et al. Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms. *Mol Psychiatry* 2024;29:16. doi: 10.1038/s41380-024-02554-0 PMID: 38678084
- 81 Peluso MJ, Sans HM, Forman CA, et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. *Neuro Neurol Neuroimmunol Neuroinflamm* 2022;9:e200003. doi: 10.1212/NXI.0000000000200003 PMID: 35701186
- 82 Boparai MS, Musheyev B, Hou W, Mehler MF, Duong TQ. Brain MRI findings in severe COVID-19 patients: a meta-analysis. *Front Neurol* 2023;14:1258352. doi: 10.3389/fneur.2023.1258352 PMID: 37900601

- 83 Nersesjan V, Fonsmark L, Christensen RHB, et al. Neuropsychiatric and cognitive outcomes in patients 6 months after COVID-19 requiring hospitalization compared with matched control patients hospitalized for non-COVID-19 illness. *JAMA Psychiatry* 2022;79:97. doi: 10.1001/jamapsychiatry.2022.0284 PMID: 35319743
- 84 Bierbauer W, Lüscher J, Scholz U. Illness perceptions in long-COVID: A cross-sectional analysis in adults. *Cogent Psychol* 2022;9:2105007. doi: 10.1080/23311908.2022.2105007.
- 85 Engelmann P, Löwe B, Brehm TT, et al. Risk factors for worsening of somatic symptom burden in a prospective cohort during the COVID-19 pandemic. *Front Psychol* 2022;13:1022203. doi: 10.3389/fpsyg.2022.1022203 PMID: 36337508
- 86 Mills F, Bhogal JK, Dennis A, et al. The effects of messaging on long COVID expectations: An online experiment. *Health Psychol* 2022;41:63. doi: 10.1037/hea0001230 PMID: 36107667
- 87 Rozenkrantz L, Kube T, Bernstein MH, Gabrieli JDE. How beliefs about coronavirus disease (COVID) influence COVID-like symptoms? - A longitudinal study. *Health Psychol* 2022;41:26. doi: 10.1037/hea0001219 PMID: 35849379
- 88 Joffe AR, Elliott A. Long COVID as a functional somatic symptom disorder caused by abnormally precise prior expectations during Bayesian perceptual processing: A new hypothesis and implications for pandemic response. *SAGE Open Med* 2023;11:20503121231194400. doi: 10.1177/20503121231194400 PMID: 37655303
- 89 Lemogne C, Gouraud C, Pitron V, Ranque B. Why the hypothesis of psychological mechanisms in long COVID is worth considering. *J Psychosom Res* 2023;165:111135. doi: 10.1016/j.jpsychores.2022.111135 PMID: 36623391
- 90 Garmoe W, Rao K, Gorter B, Kantor R. Neurocognitive impairment in post-COVID-19 condition in adults: narrative review of the current literature. *Arch Clin Neuropsychol* 2024;39:89. doi: 10.1093/arclin/aeae017 PMID: 38520374
- 91 Löwe B, Toussaint A, Rosmalen JGM, et al. Persistent physical symptoms: definition, genesis, and management. *Lancet* 2024;403:62. doi: 10.1016/S0140-6736(24)00623-8 PMID: 38879263
- 92 Vyas CM, Wang S, Menor AM, et al. Association between childhood abuse and risk of post-COVID-19 conditions: Results from three large prospective cohort studies. *Brain Behav Immun* 2025;123:50. doi: 10.1016/j.bbi.2024.08.046 PMID: 39191351
- 93 Kachaner A, Lemogne C, Dave J, Ranque B, de Broucker T, Meppiel E. Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19). *J Neurol Neurosurg Psychiatry* 2022;93:80. doi: 10.1136/jnnp-2021-327899 PMID: 36008115
- 94 Whiteside DM, Naini SM, Basso MR, et al. Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection part 2: Psychological functioning. *Clin Neuropsychol* 2022;36:47. doi: 10.1080/13854046.2022.2030411 PMID: 35098861
- 95 Fry L, Logemann A, Waldron E, et al. Emotional functioning in long COVID: Comparison to post-concussion syndrome using the Personality Assessment Inventory. *Clin Neuropsychol* 2024;38:83. doi: 10.1080/13854046.2023.2264546 PMID: 37838973
- 96 Liu J, Gill NS, Teodorczuk A, Li ZJ, Sun J. The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials. *J Affect Disord* 2019;245:112. doi: 10.1016/j.jad.2018.10.114 PMID: 30368076
- 97 Ballering A, Olde Hartman T, Rosmalen J. Long COVID-19, persistent somatic symptoms and social stigmatisation. *J Epidemiol Community Health* 2021;75:4. doi: 10.1136/jech-2021-216643 PMID: 33622802
- 98 Macpherson K, Cooper K, Harbour J, Mahal D, Miller C, Nairn M. Experiences of living with long COVID and of accessing healthcare services: a qualitative systematic review. *BMJ Open* 2022;12:e050979. doi: 10.1136/bmjopen-2021-050979 PMID: 35017239
- 99 Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun* 2022;101:135. doi: 10.1016/j.bbi.2021.12.020 PMID: 34973396
- 100 Centers for Disease Control and Prevention. Long COVID in adults: United States, 2022. NCHS Data Brief No 480. 2023. <https://www.cdc.gov/nchs/data/databriefs/db480.pdf>
- 101 Hampshire A, Trender W, Grant JE, et al. Item-level analysis of mental health symptom trajectories during the COVID-19 pandemic in the UK: Associations with age, sex and pre-existing psychiatric conditions. *Compr Psychiatry* 2022;114:152298. doi: 10.1016/j.comppsych.2022.152298 PMID: 35123177
- 102 Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. *Pathogens* 2022;11:1. doi: 10.3390/pathogens11020269 PMID: 35215212
- 103 Matias-Guiu JA, Herrera E, González-Nosti M, et al. Development of criteria for cognitive dysfunction in post-COVID syndrome: the IC-CoDi-COVID approach. *Psychiatry Res* 2023;319:115006. doi: 10.1016/j.psychres.2022.115006 PMID: 36521337
- 104 Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. *Lancet Reg Health West Pac* 2023;38:100836. doi: 10.1016/j.lanwpc.2023.100836. PMID: 37457901
- 105 Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. *Nat Med* 2022;28:15. doi: 10.1038/s41591-022-02001-z PMID: 36138154
- 106 Thompson EJ, Stafford J, Moltrecht B, et al. Psychological distress, depression, anxiety, and life satisfaction following COVID-19 infection: evidence from 11 UK longitudinal population studies. *Lancet Psychiatry* 2022;9:906. doi: 10.1016/S2215-0366(22)00307-8 PMID: 36244359
- 107 Becker JH, Lin JJ, Doernberg M, et al. Assessment of cognitive function in patients after COVID-19 infection. *JAMA Netw Open* 2021;4:e2130645. doi: 10.1001/jamanetworkopen.2021.30645 PMID: 34677597
- 108 Hampshire A, Chatfield DA, MPhil AM, et al. Cambridge NeuroCOVID Group, the NIHR COVID-19 BioResource, and Cambridge NIHR Clinical Research Facility. Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort. *EClinicalMedicine* 2022;47:101417. doi: 10.1016/j.eclinm.2022.101417 PMID: 35505938
- 109 Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. *EClinicalMedicine* 2021;39:101044. doi: 10.1016/j.eclinm.2021.101044 PMID: 34316551
- 110 Liu YH, Chen Y, Wang QH, et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. *JAMA Neurol* 2022;79:17. doi: 10.1001/jamaneurol.2022.0461 PMID: 35258587
- 111 Badenoch JB, Rengasamy ER, Watson C, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. *Brain Commun* 2021;4:fcab297. doi: 10.1093/braincomms/fcab297 PMID: 35169700
- 112 Marchi M, Grenzi P, Serafini V, et al. Psychiatric symptoms in Long-COVID patients: a systematic review. *Front Psychiatry* 2023;14:1138389. doi: 10.3389/fpsyg.2023.1138389 PMID: 37415689
- 113 Zakia H, Pradana K, Iskandar S. Risk factors for psychiatric symptoms in patients with long COVID: A systematic review. *PLoS One* 2023;18:e0284075. doi: 10.1371/journal.pone.0284075 PMID: 37027455
- 114 Nersesjan V, Christensen RHB, Kondziella D, Benros ME. COVID-19 and risk for mental disorders among adults in Denmark. *JAMA Psychiatry* 2023;80:86. doi: 10.1001/jamapsychiatry.2023.1265 PMID: 37223890
- 115 Hampshire A, Azor A, Atchison C, et al. Cognition and memory after Covid-19 in a large community sample. *N Engl J Med* 2024;390:18. doi: 10.1056/NEJMoa2311330 PMID: 38416429
- 116 Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. *Int J Environ Res Public Health* 2022;19:1. doi: 10.3390/ijerph191912422 PMID: 36231717
- 117 Walker VM, Patalay P, Cuitun Coronado JJ, et al. Longitudinal Health and Wellbeing COVID-19 National Core Study. COVID-19 and mental illnesses in vaccinated and unvaccinated people. *JAMA Psychiatry* 2024;81:80. doi: 10.1001/jamapsychiatry.2024.2339 PMID: 39167370
- 118 Xie Y, Choi T, Al-Aly Z. Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras. *N Engl J Med* 2024;391:25. doi: 10.1056/NEJMoa2403211 PMID: 39018527
- 119 Jacobs ET, Catalfamo CJ, Colombo PM, et al. Pre-existing conditions associated with post-acute sequelae of COVID-19. *J Autoimmun* 2023;135:102991. doi: 10.1016/j.jaut.2022.102991 PMID: 36634460
- 120 Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. *Nat Med* 2023;29:43. doi: 10.1038/s41591-022-02156-9 PMID: 36797482
- 121 Liu TC, Yoo SM, Sim MS, Motwani Y, Viswanathan N, Wenger NS. Perceived cognitive deficits in patients with symptomatic SARS-CoV-2 and their association with post-COVID-19 condition. *JAMA Netw Open* 2023;6:e2311974. doi: 10.1001/jamanetworkopen.2023.11974 PMID: 37145596
- 122 Wang S, Quan L, Chavarro JE, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. *JAMA Psychiatry* 2022;79:91. doi: 10.1001/jamapsychiatry.2022.2640 PMID: 36069885
- 123 Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS Med* 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773 PMID: 34582441
- 124 Wang S, Quan L, Ding M, et al. Depression, worry, and loneliness are associated with subsequent risk of hospitalization for COVID-19: a prospective study. *Psychol Med* 2023;53:31. doi: 10.1017/S0033291722000691 PMID: 35586906
- 125 Rouquette A, Descarpentry A, Dione F, et al. EpiCoV Study Group. Comparison of depression and anxiety following self-reported COVID-19-like symptoms vs SARS-CoV-2 seropositivity in France. *JAMA Netw Open* 2023;6:e2312892. doi: 10.1001/jamanetworkopen.2023.12892 PMID: 37166797
- 126 Matta J, Robineau O, Wiernik E, et al. Depression and anxiety before and at the beginning of the COVID-19 pandemic and incident persistent symptoms: a prospective population-based cohort study. *Mol Psychiatry* 2023;28:71. doi: 10.1038/s41380-023-02179-9 PMID: 37464077
- 127 Casey JA, Schwartz BS, Stewart WF, Adler NE. Using electronic health records for population health research: a review of methods and applications. *Annu Rev Public Health* 2016;37:81. doi: 10.1146/annurev-pubhealth-032315-021353 PMID: 26667605
- 128 American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. fifth edition, text revision. APA, 2022.
- 129 Braun M, Tupper D, Kaufmann P, et al. Neuropsychological assessment: a valuable tool in the diagnosis and management of neurological, neurodevelopmental, medical, and psychiatric disorders. *Cogn Behav Neurol* 2011;24:14. doi: 10.1097/WNN.0b013e3182351289 PMID: 21945982
- 130 Board on the Health of Select Populations, Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness*. National Academies Press, 2015.
- 131 Hill NL, Mogile J, Wion R, et al. Subjective cognitive impairment and affective symptoms: a systematic review. *Gerontologist* 2016;56:27. doi: 10.1093/geront/gnw091 PMID: 27342440
- 132 Heesackers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. *JAMA* 2022;327:65. doi: 10.1001/jama.2022.0040 PMID: 35072716
- 133 Honarmand K, Lalli RS, Priestap F, et al. Natural history of cognitive impairment in critical illness survivors. A systematic review. *Am J Respir Crit Care Med* 2020;202:201. doi: 10.1164/rccm.201904-0816CI PMID: 32078780

- 134 Al-Aly Z, Rosen CJ. Long Covid and impaired cognition - more evidence and more work to do. *N Engl J Med* 2024;390:60. doi: 10.1056/NEJMe2400189 pmid: 38416434
- 135 Bland AR, Barraclough M, Trender WR, et al. Profiles of objective and subjective cognitive function in Post-COVID Syndrome, COVID-19 recovered, and COVID-19 naïve individuals. *Sci Rep* 2024;14. doi: 10.1038/s41598-024-62050-x pmid: 38862569
- 136 Phlaja RE, Kauhanen LS, Ollila HS, et al. Associations of subjective and objective cognitive functioning after COVID-19: A six-month follow-up of ICU, ward, and home-isolated patients. *Brain Behav Immun Health* 2023;27:100587. doi: 10.1016/j.bbih.2023.100587 pmid: 36624888
- 137 World Health Organization. *Clinical management of COVID-19: living guideline, 13 January 2023*. WHO, 2023.
- 138 Becker JH, Lin JJ, Twumasi A, et al. Greater executive dysfunction in patients post-COVID-19 compared to those not infected. *Brain Behav Immun* 2023;114:7. doi: 10.1016/j.bbih.2023.08.014 pmid: 37586567
- 139 Cheetham NJ, Penfold R, Giunchiglia V, et al. The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study. *EClinicalMedicine* 2023;62:102086. doi: 10.1016/j.eclinm.2023.102086 pmid: 37654669
- 140 Crivelli L, Calandri I, Corvalán N, et al. Cognitive consequences of COVID-19: results of a cohort study from South America. *Arq Neuropsiquiatr* 2022;80:7. doi: 10.1590/0004-282x-2021-0320 pmid: 34816972
- 141 Delgado-Alonso C, Cuevas C, Oliver-Mas S, et al. Fatigue and cognitive dysfunction are associated with occupational status in Post-COVID syndrome. *Int J Environ Res Public Health* 2022;19. doi: 10.3390/ijerph192013368 pmid: 36293950
- 142 Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol* 2021;8:85. doi: 10.1002/actn.3.51350 pmid: 33755344
- 143 Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: Evidence of mood & cognitive impairment. *Brain Behav Immun Health* 2021;17:100347. doi: 10.1016/j.bbih.2021.100347 pmid: 34549199
- 144 Ortell P, Benso F, Ferrazzoli D, et al. Global slowness and increased intra-individual variability are key features of attentional deficits and cognitive fluctuations in post COVID-19 patients. *Sci Rep* 2022;12. doi: 10.1038/s41598-022-17463-x pmid: 35907947
- 145 Poletti S, Palladini M, Mazza MG, et al. COVID-19 BioB Outpatient Clinic Study group. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life. *Eur Arch Psychiatry Clin Neurosci* 2022;272:82. doi: 10.1007/s00406-021-01346-9 pmid: 34698871
- 146 Zhao S, Martin EM, Reuken PA, et al. Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study. *EClinicalMedicine* 2024;68:102434. doi: 10.1016/j.eclinm.2024.102434 pmid: 38318123
- 147 Tavares-Júnior JW, de Souza ACC, Borges JWP, et al. COVID-19 associated cognitive impairment: A systematic review. *Cortex* 2022;152:97. doi: 10.1016/j.cortex.2022.04.006 pmid: 35537236
- 148 Perrottelli A, Sansone N, Giordano GM, et al. Cognitive impairment after post-acute COVID-19 infection: a systematic review of the literature. *J Pers Med* 2022;12. doi: 10.3390/jpm12122070 pmid: 36556290
- 149 Panagea E, Messinis L, Petri MC, et al. Neurocognitive Impairment in Long COVID: A Systematic Review. *Arch Clin Neuropsychol* 2025;40:49. doi: 10.1093/achn/ckaa028 pmid: 38850628
- 150 Sneller MC, Liang CJ, Marques AR, et al. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. *Ann Intern Med* 2022;175:79. doi: 10.7326/M21-4905 pmid: 35605238
- 151 Austin TA, Thomas ML, Lu M, et al. Meta-analysis of cognitive function following non-severe SARS-CoV-2 infection. *Neuropsychol Rev* 2024. doi: 10.1007/s10655-024-09642-6 pmid: 38862725
- 152 Knapp SAB, Austin DS, Aita SL, et al. Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysis. *J Neurol Neurosurg Psychiatry* 2024;95:16. doi: 10.1136/jnnp-2024-333950 pmid: 38914455
- 153 Sweet JJ, Heilbronner RL, Morgan JE, et al. Conference Participants. American Academy of Clinical Neuropsychology (AACN) 2021 consensus statement on validity assessment: Update of the 2009 AACN consensus conference statement on neuropsychological assessment of effort, response bias, and malingering. *Clin Neuropsychol* 2021;35:106. doi: 10.1080/13854046.2021.1896036 pmid: 33823750
- 154 Whiteside DM, Basso MR, Shen C, et al. The relationship between performance validity testing, external incentives, and cognitive functioning in long COVID. *J Clin Exp Neuropsychol* 2024;46:15. doi: 10.1080/13803395.2024.2312625 pmid: 38299800
- 155 Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic in 2020. *J Affect Disord* 2022;296:76. doi: 10.1016/j.jad.2021.09.098 pmid: 34600966
- 156 Ettman CK, Cohen GH, Abdalla SM, et al. Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of U.S. adults. *Lancet Reg Health Am* 2022;5:100091. doi: 10.1016/j.lana.2021.100091 pmid: 34635882
- 157 Wang Y, Su B, Xie J, Garcia-Rizo C, Prieto-Alhambra D. Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population. *Nat Hum Behav* 2024;8:87. doi: 10.1038/s41562-024-01853-4 pmid: 38514769
- 158 Parker AM, Sricharoenchai T, Raparla S, Schneek KW, Bienvenu OJ, Needham DM. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. *Crit Care Med* 2015;43:9. doi: 10.1097/CCM.0000000000000882 pmid: 25654178
- 159 Rabiee A, Nikayin S, Hashem MD, et al. Depressive symptoms after critical illness: a systematic review and meta-analysis. *Crit Care Med* 2016;44:53. doi: 10.1097/CCM.0000000000001811 pmid: 27153046
- 160 Hodgson CL, Higgins AM, Bailey MJ, et al. COVID-Recovery Study Investigators and the ANZICS Clinical Trials Group. Comparison of 6-month outcomes of survivors of COVID-19 versus non-COVID-19 critical illness. *Am J Respir Crit Care Med* 2022;205:68. doi: 10.1164/rccm.202110-2335OC pmid: 35258437
- 161 Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term effects of COVID-19 on mental health: A systematic review. *J Affect Disord* 2022;299:25. doi: 10.1016/j.jad.2021.11.031 pmid: 34798148
- 162 Naik H, Tran KC, Staples JA, Perlis RH, Levin A. Psychiatric Symptoms, Treatment Uptake, and Barriers to Mental Health Care Among US Adults With Post-COVID-19 Condition. *JAMA Netw Open* 2024;7:e248481. doi: 10.1001/jamanetworkopen.2024.8481 pmid: 38662370
- 163 Del Brutto OH, Rumbela DA, Recalde BY, Mera RM. Cognitive sequelae of long COVID may not be permanent: A prospective study. *Eur J Neurol* 2022;29:21. doi: 10.1111/ene.15215 pmid: 34918425
- 164 Liu YH, Wang YR, Wang QH, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. *Mol Neurodegener* 2021;16. doi: 10.1186/s13024-021-00469-w pmid: 34281568
- 165 Liu YH, Wu QX, Wang QH, et al. Tracking cognitive trajectories in older survivors of COVID-19 up to 2.5 years post-infection. *Nat Aging* 2024;4:93. doi: 10.1038/s43587-024-00667-3 pmid: 38987646
- 166 Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R. Association of COVID-19 with new-onset Alzheimer's disease. *J Alzheimers Dis* 2022;89:4. doi: 10.3233/JAD-220717 pmid: 35912749
- 167 Gollop C, Zingel R, Jacob L, Smith L, Koyanagi A, Kostev K. Incidence of newly-diagnosed dementia after COVID-19 infection versus acute upper respiratory infection: a retrospective cohort study. *J Alzheimers Dis* 2023;93:40. doi: 10.3233/JAD-221271 pmid: 37212106
- 168 Shan D, Wang C, Crawford T, Holland C. Temporal association between COVID-19 infection and subsequent new-onset dementia in older adults: a systematic review and meta-analysis. *SSRN* 4716751doi: 10.2139/ssrn.4716751.
- 169 Cheng AL, Anderson J, Didehban N, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of mental health symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). *PM R* 2023;15:604. doi: 10.1002/pmrj.13085 pmid: 37937672
- 170 Fine JS, Ambrose AF, Didehban N, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). *PM R* 2022;14:111. doi: 10.1002/pmrj.12745 pmid: 34902226
- 171 Holmes EA, O'Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry* 2020;7:60. doi: 10.1016/S2215-0366(20)30168-1 pmid: 32304649
- 172 Chou R, Dana T, Ahmed AY, et al. Long COVID models of care. Technical Brief No 45. 2024. <https://www.ncbi.nlm.nih.gov/books/NBK603663/>.
- 173 Price E, Hollis N, Salganik J, et al. Implementing a multidisciplinary Post-COVID clinic in a small community environment. *Arch Rehabil Res Clin Transl* 2023;5:100270. doi: 10.1016/j.arct.2023.100270 pmid: 37744201
- 174 Agency for Healthcare Research and Quality. AHRQ awards additional grants to expand access to care for people with Long COVID. 2024. <https://www.ahrq.gov/news/newsletters/e-newsletter/919.html>.
- 175 Koterba CH, Considine CM, Becker JH, et al. Neuropsychology practice guidance for the neuropsychiatric aspects of Long COVID. *Clin Neuropsychol* 2025;39:98. doi: 39177216
- 176 Cysique LA, Łojek E, Cheung TCK, et al. NeuroCOVID International Neuropsychology Taskforce. Assessment of neurocognitive functions, olfaction, taste, mental, and psychosocial health in COVID-19 in adults: recommendations for harmonization of research and implications for clinical practice. *J Int Neuropsychol Soc* 2022;28:60. doi: 10.1017/S1355617721000862 pmid: 34365990
- 177 Gorst SL, Seylanova N, Dodd SR, et al. PC-COS study group. Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study. *Lancet Respir Med* 2023;11:14. doi: 10.1016/S2213-2600(23)00370-3 pmid: 37926103
- 178 Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:7. doi: 10.1001/archinte.166.10.1092 pmid: 16717171
- 179 Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): Development and initial psychometric evaluation. *J Trauma Stress* 2015;28:98. doi: 10.1002/jts.22059 pmid: 26606250
- 180 Broadbent DE, Cooper PF, Fitzgerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. *Br J Clin Psychol* 1982;21:16. doi: 10.1111/j.2044-8260.1982.tb01421.x pmid: 7126941
- 181 Wong A, Nyenhuis D, Black SE, et al. Montreal Cognitive Assessment 5-minute protocol is a brief, valid, reliable, and feasible cognitive screen for telephone administration. *Stroke* 2015;46:64. doi: 10.1161/STROKEAHA.114.007253 pmid: 25700290
- 182 Al-Jabr H, Hawke LD, Thompson DR, et al. Interventions to support mental health in people with long COVID: a scoping review. *BMC Public Health* 2023;23. doi: 10.1186/s12889-023-16079-8 pmid: 37340400

- 183 Sugita S, Hata K, Kodaïarasu K, et al. Psychological treatments for mental health symptoms associated with COVID-19 infection: A scoping review. *PCN Rep* 2024;3:e223. doi: 10.1002/pcn5.223 pmid: 38962000
- 184 Chandan JS, Brown KR, Simms-Williams N, et al. TLC Study. Non-Pharmacological Therapies for Post-Viral Syndromes, Including Long COVID: A Systematic Review. *Int J Environ Res Public Health* 2023;20:. doi: 10.3390/ijerph20043477 pmid: 36834176
- 185 Kuut TA, Müller F, Csorba I, et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following coronavirus disease 2019: results of a randomized controlled trial. *Clin Infect Dis* 2023;77:-95. doi: 10.1093/cid/ciad257 pmid: 37155736
- 186 McGregor G, Sandhu H, Bruce J, et al. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial. *BMJ* 2024;384:e076506. doi: 10.1136/bmj-2023-076506 pmid: 38325873
- 187 Santana K, França E, Sato J, et al. Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC). *Brain Stimul* 2023;16:-7. doi: 10.1016/j.brs.2023.01.1672 pmid: 36693536
- 188 Knopman DS, Laskowitz DT, Koltai DC, et al. RECOVER-NEURO: study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC). *Trials* 2024;25:. doi: 10.1186/s13063-024-08156-z pmid: 38755688
- 189 Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. *Eur Neuropsychopharmacol* 2022;54:-6. doi: 10.1016/j.euroneuro.2021.09.009 pmid: 34634679
- 190 O'Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort: an interventional pre-post study. *Brain Behav Immun Health* 2022;24:100485. doi: 10.1016/j.bbih.2022.100485 pmid: 35814187
- 191 Bonilla H, Tian L, Marconi VC, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. *Int Immunopharmacol* 2023;124(Pt B):110966. doi: 10.1016/j.intimp.2023.110966 pmid: 37804660
- 192 Naik H, Cooke E, Boulter T, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia. *BMJ Open* 2024;14:e085272. doi: 10.1136/bmjopen-2024-085272 pmid: 38740499
- 193 Hawke LD, Nguyen ATP, Ski CF, Thompson DR, Ma C, Castle D. Interventions for mental health, cognition, and psychological wellbeing in long COVID: a systematic review of registered trials. *Psychol Med* 2022;52:-40. doi: 10.1017/S0033291722002203 pmid: 35768406
- 194 Chee YJ, Fan BE, Young BE, Dalan R, Lye DC. Clinical trials on the pharmacological treatment of long COVID: A systematic review. *J Med Virol* 2023;95:e28289. doi: 10.1002/jmv.28289 pmid: 36349400
- 195 Fernández-de-Las-Peñas C, Nijs J, Giordano R, Arendt-Nielsen L. Precision management of post-COVID pain: An evidence and clinical-based approach. *Eur J Pain* 2023;27:-25. doi: 10.1002/ejp.2095 pmid: 36852606
- 196 Centers for Disease Control and Prevention. Clinical overview of long COVID <https://www.cdc.gov/covid/hcp/clinical-overview/index.html>.
- 197 Sacks-Zimmerman A, Bergquist TF, Farr EM, Cornwell MA, Kanellopoulos D. Rehabilitation of neuropsychiatric symptoms in patients with Long COVID: position statement. *Arch Phys Med Rehabil* 2023;104:-4. doi: 10.1016/j.apmr.2022.10.001 pmid: 36272444
- 198 National Academies of Sciences, Engineering, and Medicine. Long COVID: Examining long-term health effects of COVID-19 and implications for the Social Security Administration: Proceedings of a workshop. 2022. <https://pubmed.ncbi.nlm.nih.gov/36260712/>.